Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of PainTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the publication of ...

Core Insights - Avicanna Inc. announces the resignation of Mr. Paul Fornazzari from its board of directors and the appointment of Mr. Michael Kott, effective January 1, 2026 [1][2] Group 1: Leadership Changes - Mr. Michael Kott brings over 35 years of experience in international capital markets, corporate finance, and fundraising, having founded CM-Equity AG, which transitioned into a global single-family office in 2025 [2] - Mr. Kott has a strong background in governance, compliance, capital markets transactions, IPOs, and cross-border investments, and is an active independent investor across various sectors including biopharma and technology [2] Group 2: Company Vision and Strategy - Mr. Kott expresses optimism about Avicanna's future, highlighting the company's position in the natural pharmaceuticals megatrend and the potential impact of recent communications from the White House regarding cannabis reclassification in the US [3] - The CEO of Avicanna, Aras Azadian, acknowledges Mr. Fornazzari's contributions and welcomes Mr. Kott, emphasizing the importance of his expertise in capital markets for the company's growth and shareholder value [4] Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing cannabinoid-based products for the global medical and pharmaceutical markets, with over thirty proprietary, evidence-based finished products [5] - The company operates a medical cannabis formulary (RHO Phyto™) and a medical cannabis care platform (MyMedi.ca), aimed at enhancing patient care and education [5] - Avicanna has a pharmaceutical pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [5]

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development (R&D), clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [2][6] R&D and Clinical Development - Avicanna has established a scientific platform that includes over thirty proprietary, evidence-based finished products and supports four commercial stage business pillars [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary cannabinoid formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, contributing to improved patient access and support programs [6] - The MyMedi.ca platform aims to enhance the medical cannabis patient journey, providing bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Active pharmaceutical ingredients are supplied by Avicanna's subsidiary, Santa Marta Golden Hemp SAS, which provides high-quality CBD, THC, and CBG for various applications [9]

Core Insights - Avicanna Inc. supports President Trump's executive order to reclassify cannabis from Schedule I to Schedule III, emphasizing the importance of scientific research in the field of cannabinoid-based medicine [2][3] - The company has made significant advancements in research and development, clinical development, and medical affairs, positioning itself for future growth and innovation in cannabinoid therapies [3][6] R&D and Clinical Development - Avicanna has established a robust scientific platform leading to the commercialization of over thirty proprietary, evidence-based products, including a diverse range of cannabinoid formulations [5] - The company is executing a balanced clinical development strategy, with approximately 450 patients enrolled in a real-world evidence study evaluating outcomes related to pain, sleep, anxiety, and depression [6] - A Phase II randomized controlled trial for evaluating arthritic pain using Avicanna's proprietary formulations commenced in December 2025 [6] Medical Affairs and Education - Avicanna has expanded its engagement with healthcare professionals through educational events and initiatives, enhancing patient access and support programs [6][9] - The MyMedi.ca platform aims to improve the medical cannabis patient journey, offering bilingual pharmacist-led support and specialty services for distinct patient groups [9] Pharmaceutical Pipeline - The company is developing a pipeline of proprietary, indication-specific cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [9] - Avicanna's active pharmaceutical ingredients are supplied by its subsidiary, ensuring a reliable source of high-quality CBD, THC, and CBG for various applications [9]

Core Points - Avicanna Inc. has appointed Nick Hilborn as Interim Chief Financial Officer, succeeding Phillip Cardella who transitions to a consulting role [1][2] - The CEO, Aras Azadian, expressed gratitude for Cardella's contributions during transformative years and highlighted Hilborn's familiarity with the company and its culture [2] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the global medical and pharmaceutical markets [3] - The company has a scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products and four commercial stage business pillars [3] Product and Service Offerings - The RHO Phyto™ formulary includes a diverse range of proprietary products with various cannabinoid ratios, available nationwide in Canada and expanding internationally [6] - MyMedi.ca is a medical cannabis care platform aimed at enhancing the patient journey, featuring a diverse product portfolio and bilingual pharmacist-led support programs [6] - Avicanna has developed a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [6] - The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various applications, forming part of Avicanna's supply chain [6]

Core Insights - The United States Patent and Trademark Office (USPTO) has issued Patent No. US 12,343,315 B2 to Avicanna Inc. for its topical cannabinoid compositions aimed at promoting clear skin [1][2] - The patent covers a topical gel formulation that combines cannabinoids with antioxidants, anti-microbial agents, and anti-inflammatory agents, targeting skin diseases such as acne, wrinkles, rosacea, and erythema [2] - Avicanna's CEO expressed enthusiasm about the patent, highlighting its potential in the company's commercial platforms and pharmaceutical pipeline [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4] - The company has a robust scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] - Avicanna operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and a subsidiary (Santa Marta Golden Hemp SAS) that supplies active pharmaceutical ingredients [4][7]

Core Viewpoint - Avicanna Inc. has successfully closed a non-brokered private placement offering, raising $1,000,000 through the sale of 4,000,000 units at a price of $0.25 per unit, which includes common shares and warrants [1][2]. Group 1: Offering Details - The offering consists of 4,000,000 units priced at $0.25 each, resulting in total gross proceeds of $1,000,000 [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of one common share at an exercise price of $0.30 until July 16, 2028 [1]. - The securities from the offering are subject to a four-month hold period under Canadian securities laws and require necessary approvals, including from the Toronto Stock Exchange [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general working capital, administrative expenses, production and manufacturing expenditures, and research and clinical development [2]. Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4]. - The company has a scientific platform that supports over thirty proprietary, evidence-based products and operates four commercial-stage business pillars [4]. - Avicanna's product offerings include a diverse range of cannabinoid-based formulations and a medical cannabis care platform aimed at enhancing patient experiences [6].

Core Viewpoint - Avicanna Inc. has successfully closed a non-brokered private placement offering, raising $1,000,000 through the sale of 4,000,000 units at a price of $0.25 per unit, which includes common shares and warrants [1][2]. Group 1: Offering Details - The offering consists of 4,000,000 units priced at $0.25 each, resulting in total gross proceeds of $1,000,000 [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of additional shares at an exercise price of $0.30 until July 16, 2028 [1]. - The securities from the offering are subject to a four-month hold period under Canadian securities laws and require necessary approvals, including from the Toronto Stock Exchange [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general working capital, administrative expenses, production and manufacturing costs, and research and clinical development [2]. Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products for the medical and pharmaceutical markets [4]. - The company has a scientific platform that supports over thirty proprietary products and operates four commercial-stage business pillars [4]. - Avicanna's product offerings include a diverse range of cannabinoid-based formulations and a medical cannabis care platform aimed at enhancing patient support and education [6].

Core Insights - Avicanna Inc. has entered into a Sponsored Research Agreement to sponsor a randomized controlled trial (RCT) on the effectiveness of oral cannabis extracts for osteoarthritic pain, led by Dr. Hance Clarke [1][2] Group 1: Study Details - The RCT aims to determine the feasibility of a blinded, randomized, placebo-controlled, 3-arm trial of oral cannabinoids for improving pain interference in patients with hip and/or knee osteoarthritis [3] - The study is expected to start in Fall 2025 and will assess patient enrollment, protocol adherence, and data completeness [2][3] Group 2: Funding and Sponsorship - The RCT is funded by a grant from the Canadian Institutes of Health Research (CIHR) and is sponsored by Avicanna, which will provide its proprietary CBD and THC capsules produced under Good Manufacturing Practices (GMP) for the trial [4] Group 3: Company Overview - Avicanna is a biopharmaceutical company focused on the development and commercialization of cannabinoid-based products, with over thirty proprietary, evidence-based finished products [5] - The company operates multiple business pillars, including a medical cannabis formulary (RHO Phyto™), a medical cannabis care platform (MyMedi.ca), a pharmaceutical pipeline, and active pharmaceutical ingredients supplied by its subsidiary [5]

Core Insights - Avicanna Inc. has reported its first profitable quarter in Q1 2025, marking a significant milestone for the company [1][2][7] Financial Highlights - The company achieved a net income of $74,154 and a comprehensive income of $876,092, attributed to cost efficiencies and margin improvements [7] - Adjusted positive EBITDA was approximately $431,000, a substantial increase from about $18,000 in Q1 2024 [7] - Gross profit reached $3.54 million, reflecting a 7% year-over-year increase, with consolidated gross margins improving to 56% from 51% in Q1 2024 [7] - Revenue for the quarter was $6.32 million, a slight 2% decrease compared to Q1 2024, alongside a 5% reduction in general and administrative expenses [7] Corporate Developments - Avicanna expanded its Canadian portfolio to 42 proprietary commercial SKUs, a 35% increase from 31 SKUs in the same period in 2024, while maintaining a total of 135 commercial listings [4] - The company announced a scientific and medical affairs collaboration with Aspeya to enhance research and medical initiatives related to medical cannabis in Canada [5] Product and Service Offerings - The RHO Phyto™ formulary includes a diverse range of proprietary products with various cannabinoid delivery methods, supported by ongoing education for patients and the medical community [8] - MyMedi.ca serves as a medical cannabis care platform aimed at improving patient access and support, featuring a diverse product portfolio and specialty services for distinct patient groups [9] Research and Development - Avicanna is advancing a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [12] - The company’s majority-owned subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various product developments [12]